Introduction:
Kymanox is planning to expand its device design and testing facility, significantly enhancing its laboratory testing capabilities and increasing its CGxP footprint in the USA.
Features:
This demand-driven expansion represents a pivotal step in underscoring its commitment to providing comprehensive premium services for both modern and legacy combination products, such as advanced dose delivery testing and clinical trial device assembly.
The new area of the facility will enhance ability to serve by offering a more robust range of services and increased capacity. Additionally, the new space will advance expertise in sterilisation technologies, methodologies, and validation.
The expanded facility will support the assembly of advanced combination products for clinical studies, bolstering its capability to aid in the development of innovative medical treatments and technologies.
The expanded CGxP space will allow to meet the projected demand for 2025 and 2026 and provide the necessary infrastructure to broaden the service offerings.
With the construction already underway, the facility is slated for completion later in 2024.
Specifications:
Name Kymanox
Type Expansion
Year 2024
